Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Hepatitis -- Ignore unavailable to you. Want to Upgrade?

To: ghmm who wrote (297)	2/4/2018 1:19:15 AM
From: Miljenko Zuanic	Respond to of 312

Agree, do think that GLPG is right choice, but they may want to stay independent. <To me it appears there are some disagreements between the two on development> I was always intrigued how did ABBV develop their own Jak1, while they have active collaboration with GLPG? The same way, in past, how did Novartis develop anti-IL1, while they have active collaboration with REGN??? Well, it appears that bio will make deal..hope pharma will play fair! Naive and stupid!